NCT07221656Not yet recruiting
Evaluation of Prolonged Asparaginase Activity Levels After Calaspargase Pegol Administration
Source: ClinicalTrials.gov · Last updated 2 Apr 2026
Brief summary (registry, in English)
This study evaluates the median duration of therapeutic serum asparaginase activity (SAA) levels after administration of calaspargase pegol (Cal-PEG) and the potential association between peak SAA levels and duration of therapeutic levels with toxicity in pediatric patients with acute lymphoblastic leukemia or lymphoma.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 20 (estimated)
- First submitted
- 24 Oct 2025
- Start date
- 1 Feb 2027
- Primary completion date
- 31 Dec 2028
- Lead sponsor
- Mayo Clinic
- NCT number
- NCT07221656
What you commit to
- Study type: Observational
- Planned participants: 20
- From 1 Feb 2027 to the primary completion date, 31 Dec 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Age
- Age \> 21 years
Other
- Patients who are actively enrolled on Children's Oncology Group (COG) trial AALL1732 in an inotuzumab containing arm
- Pregnancy
Who the study is looking for
- Acute lymphoblastic leukemia/lymphoma being treated by the pediatric hematology team
- Receiving calaspargase as part of treatment for malignancy
Age in the registry: - to 21 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Mayo Clinic in Rochester Coordinator of this site? Confirm its status | Rochester | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.